Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients.

ABSTRACT:

Background

The standard of care for glioblastoma (GBM) is maximal safe resection followed by radiation therapy with chemotherapy. Currently, contrast-enhanced MRI is used to define primary treatment volumes for surgery and radiation therapy. However, enhancement does not identify the tumor entirely, resulting in limited local control. Proton spectroscopic MRI (sMRI), a method reporting endogenous metabolism, may better define the tumor margin. Here, we develop a whole-brain sMRI pipeline and validate sMRI metrics with quantitative measures of tumor infiltration.

Methods

Whole-brain sMRI metabolite maps were coregistered with surgical planning MRI and imported into a neuronavigation system to guide tissue sampling in GBM patients receiving 5-aminolevulinic acid fluorescence-g

SUBMITTER: Cordova JS 

PROVIDER: S-EPMC4933486 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature